Is Brain-Derived Neurotrophic Factor (Bdnf) Val66met Polymorphism Associated With Obsessive-Compulsive Disorder? A Meta-Analysis

Wang, S; Xu, Xiaowei; Yan, Pu; Song, Meng Meng; Li, Jian

doi:10.24869/psyd.2019.141

Cited by 9 publications

(12 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main findings of our studies indicate that the Val66Met polymorphism is not associated with OCD. Two prior meta-analyses have indicated that the Val66Met polymorphism is not related to OCD, which was in agreement with our findings ( 8 , 20 ).…”

Section: Discussionsupporting

confidence: 94%

“…While previous evidence suggests that the rs6265 polymorphism is involved in the etiology of OCD, the outcomes of such studies have been inconsistent and even contradictory. Findings from the latest meta-analytic investigation by Wang et al in 2019 provide little support for the Val66Met variant as a predictor of OCD ( 8 ). In order to derive a more putative conclusion, an updated meta-analysis was performed to study the connection between the rs6265 polymorphism of the BDNF gene and the risk of OCD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Is Associated With Female Obsessive-Compulsive Disorder: An Updated Meta-Analysis of 2765 Obsessive-Compulsive Disorder Cases and 5558 Controls

et al. 2022

View full text Add to dashboard Cite

Objective: Accumulated evidence has implicated that brain-derived neurotrophic factor (BDNF) gene polymorphisms play a role in the etiology of obsessive-compulsive disorder (OCD). A single nucleotide polymorphism in the coding exon of the BDNF gene at position 66, Val66Met (rs6265), is found to be associated with OCD in different populations, but results linking Val66Met with OCD have been inconsistent and inconclusive. In our study we performed a meta-analysis to further examine whether rs6265 genetic variants are involved in the etiology of OCD.Methods: By searching databases, relevant case-control studies were retrieved; using established inclusion criteria, we selected eligible studies for analysis.Results: Thirteen studies were identified that examined the association between the rs6265 polymorphism and OCD. After statistical analyses, no significant association was found between the rs6265 polymorphism and OCD (OR = 1.07, 95% CI = 1.00–1.15, P = 0.06 for genotype; OR = 1.06, 95% CI = 0.98–1.15, P = 0.15 for allele). However, in gender-specific analysis, female Val carriers might be a risk factor for OCD (OR = 1.36, 95% CI = 1.03–1.80, P = 0.03 for genotype; OR = 1.15, 95% CI = 1.01–1.32, P = 0.04 for allele).Conclusion: Our updated meta-analysis suggests that female carriers of the Val66Met BDNF polymorphism might be more suspectable to develop OCD.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Introductionmentioning

confidence: 99%

The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Is Associated With Female Obsessive-Compulsive Disorder: An Updated Meta-Analysis of 2765 Obsessive-Compulsive Disorder Cases and 5558 Controls

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Most genetic studies have focused on the role of the brainderived neurotrophic factor (BDNF) in the pathophysiology of mental disorders, including OCD. 4 BDNF is a member of the neurotrophin family and it plays an important role in neuronal survival, differentiation, synaptic efficiency, neuronal plasticity, and neurotransmitter function. 5 The genetic variation of this gene that has been the most widely studied is 196G/A, which produces a functional change in the Val66Met amino-acid (rs6265).…”

Section: Introductionmentioning

confidence: 99%

Impact of brain-derived neurotrophic factor Val66Met polymorphism and response to escitalopram or paroxetine in obsessive–compulsive disorder

et al. 2021

View full text Add to dashboard Cite

Objective Obsessive–compulsive disorder (OCD) is a severe psychiatric disorder characterized by its heterogeneous nature and by different dimensions of obsessive–compulsive (OC) symptoms. Serotonin reuptake inhibitors (SRIs) are used to treat OCD, but up to 40% to 60% of patients do not show a significant improvement with these medications. In this study, we aimed to test the impact of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism on the efficacy of antidepressants in OCD overall, and in relation to the different OC dimensions. Methods In a 6-month prospective treatment study, 69 Caucasian OCD patients were treated with escitalopram for 24 weeks or with escitalopram for 12 weeks followed by paroxetine for an additional 12-week period. Patients were genotyped and assessed for treatment response. The main clinical outcomes were improvement of the Yale-Brown Obsessive–Compulsive Scale score and in different OC symptom dimension scores. Results The Val/Val group comprised 43 (62%) patients, the Val/Met and Met/Met group comprised 26 (38%) patients. Forty-two patients were classified as responders at 12 weeks and 38 at 24 weeks; no significant association was found between BDNF Val66Met and SRIs response at 12 and 24 weeks. In analyses of the different OC symptom dimensions, the Met allele was associated with a slightly reduced score in the aggressive/checking dimension at 6 months (P = .048). Conclusions Our findings do not support the usefulness of BDNF Val66Met genotyping to predict overall response to treatment with SRIs in OCD; they did however suggest a better outcome at 6 months for the aggressive/checking symptom dimension for patients carrying the Met allele.

show abstract

“…Altered levels of BDNF have also been related to impulsiveness in PTSD [12] and could be therefore considered a link between OCD and PTSD. However, evidence of the role of BDNF in OCD is still weak [13].…”

Section: Introductionmentioning

confidence: 99%

A Case of Comorbid PTSD and Posttraumatic OCD Treated with Sertraline-Aripiprazole Augmentation

Rossi

Niolu

Siracusano

et al. 2020

Case Reports in Psychiatry

View full text Add to dashboard Cite

Several studies report on traumatic history in Obsessive Compulsive Disorder (OCD) and comorbidity between Posttraumatic Stress Disorder (PTSD) and OCD. First-line pharmacological treatments for both OCD and PTSD are primarily based on antidepressants, including Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Noradrenaline Reuptake Inhibitors (SNRI) such as Venlafaxine for PTSD. Second-Generation Antipsychotic (SGA) augmentation has shown good outcomes for nonresponsive OCD cases. However, evidence on the use of SGA in PTSD is more limited. In the present paper, we report on comorbid OCD-PTSD successfully treated with aripiprazole augmentation of sertraline. Shared psychopathological and pharmacological aspects of the disorders are discussed.

show abstract

Is Brain-Derived Neurotrophic Factor (Bdnf) Val66met Polymorphism Associated With Obsessive-Compulsive Disorder? A Meta-Analysis

Cited by 9 publications

References 24 publications

The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Is Associated With Female Obsessive-Compulsive Disorder: An Updated Meta-Analysis of 2765 Obsessive-Compulsive Disorder Cases and 5558 Controls

The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Is Associated With Female Obsessive-Compulsive Disorder: An Updated Meta-Analysis of 2765 Obsessive-Compulsive Disorder Cases and 5558 Controls

Impact of brain-derived neurotrophic factor Val66Met polymorphism and response to escitalopram or paroxetine in obsessive–compulsive disorder

A Case of Comorbid PTSD and Posttraumatic OCD Treated with Sertraline-Aripiprazole Augmentation

Contact Info

Product

Resources

About